greeksoup/ stock research
Stock research / United States / GILD · Biological Products, (No Diagnostic Substances) · Nasdaq

Gilead Sciences, Inc. (GILD)

Gilead Sciences is a biopharmaceutical company working in virology, oncology and other therapeutic areas, with a stated focus on preventing and treating life-threatening diseases including HIV, viral hepatitis, COVID-19 and cancer. It operates in more than 35 countries and is headquartered in Foster City, California. The 2025 commercial portfolio held more than 25 therapies.

Gilead Sciences, Inc.

Gilead Sciences is a biopharmaceutical company working in virology, oncology and other therapeutic areas, with a stated focus on preventing and treating life-threatening diseases including HIV, viral hepatitis, COVID-19 and cancer. It operates in more than 35 countries and is headquartered in Foster City, California. The 2025 commercial portfolio held more than 25 therapies.

HIV

Biktarvy is a once-a-day single-tablet regimen combining bictegravir, emtricitabine and tenofovir alafenamide for HIV-1 infection. Descovy combines emtricitabine and tenofovir alafenamide, used with other antiretrovirals for treatment and also approved for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1. Genvoya adds elvitegravir and cobicistat to the same two components as a single tablet, and Odefsey pairs them with rilpivirine, a medication marketed by Janssen. Sunlenca is an HIV-1 capsid inhibitor taken as a tablet or given by subcutaneous injection, indicated as a twice-yearly treatment for heavily treatment-experienced adults with multidrug resistant HIV-1 failing their current regimen. Yeztugo is also a capsid inhibitor, indicated for pre-exposure prophylaxis in certain adults and adolescents at risk of acquiring HIV-1. Symtuza, which adds Janssen's darunavir, is commercialised by Janssen, and Gilead takes a share for the components it contributes.

Liver disease

Epclusa is a once-daily single tablet of sofosbuvir and velpatasvir for chronic hepatitis C across genotypes 1 to 6, and an authorised generic version of it is distributed by a separate Gilead subsidiary, Asegua Therapeutics. Vemlidy is a once-a-day tenofovir alafenamide tablet for chronic hepatitis B in adults and children 12 and over with compensated liver disease. Livdelzi, or seladelpar, is an oral PPAR-delta agonist for primary biliary cholangitis, used with ursodeoxycholic acid in adults who respond inadequately to it, or alone where the patient cannot tolerate it.

Oncology and the rest

Yescarta and Tecartus are CAR T-cell therapies given as intravenous infusions, Yescarta for large B-cell lymphoma and relapsed or refractory follicular lymphoma, Tecartus for relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia. Trodelvy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate given by injection, for metastatic triple-negative breast cancer after two or more prior systemic therapies and for certain hormone receptor-positive, HER2-negative breast cancer. Outside those two areas, Veklury is remdesivir, a nucleotide analog RNA polymerase inhibitor for COVID-19 in hospitalised patients and in higher-risk patients who are not hospitalised, and AmBisome is a liposomal formulation of the antifungal amphotericin B for serious invasive fungal infections. Beyond product sales, the company earns royalties on outbound licences of its intellectual property, proceeds from selling certain intellectual property, and payments from collaborations.

How the medicines are sold

There are commercial sales operations in the United States and internationally, with marketing subsidiaries in more than 35 countries. Products are marketed by the company's own commercial teams, which contact physicians, hospitals, clinics and other healthcare providers directly, and alongside third-party wholesalers, distributors and corporate partners. Third-party distributors are generally granted the exclusive right to promote a product in a territory for a set period, and most of those agreements have the distributor and Gilead working together to obtain and keep regulatory approval there. In the United States most products go exclusively through the wholesale channel, and the filing states that historically about 90 percent of gross product sales there have been to three large wholesalers, Cardinal Health, Cencora and McKesson, and their specialty distributor affiliates.

Making it

Manufacturing is split between the company's own sites and outside firms. The company's facilities include Foster City for process, method, formulation and device development and clinical supply; La Verne, California, where AmBisome is made and most commercial products are packaged and labelled for the Americas and the Pacific Rim; Oceanside for retroviral vector manufacturing; El Segundo, Santa Monica, Frederick in Maryland and Hoofddorp in the Netherlands for cell therapy products; Cork and Dublin in Ireland for commercial manufacturing, packaging, labelling, quality control and distribution to the EU and other international markets; and Edmonton in Canada for process and analytical development and active ingredient manufacture. For the majority of active ingredients and drug products, though, the company depends on contract manufacturing organisations and contract testing laboratories inside and outside the United States, using multiple contract manufacturers for most products including the HIV ones so that there are both primary and back-up suppliers and sites.

From Gilead Sciences' annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Gilead Sciences became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 30 October 2026
Revenue
$8.3 billion
+6.8% on the year · +6.4% on the quarter
Q4 FY2024Q3 FY2026
Net income
$2.4 billion
-20.4% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$1.94
-20.2% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 24 February 2026
Revenue
$29.4 billion
+2.4% on the year
FY2018FY2025
Net income
$8.5 billion
+1,672.9% on the year
FY2018FY2025
Diluted EPS
$6.78
+1,684.2% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsGilead Sciences (GILD) reported revenue of $29.4 billion for fiscal 2025, the year ended 31 December 2025, up 2.4% on the year before. Net income was $8.5 billion and diluted earnings per share $6.78. Revenue was $28.8 billion in fiscal 2024, $27.1 billion in fiscal 2023, $27.3 billion in fiscal 2022 and $27.3 billion in fiscal 2021. Net income in the same years was $480 million, $5.7 billion, $4.6 billion and $6.2 billion. Over the twelve months to 30 September 2026, Gilead Sciences reported revenue of $31.0 billion and net loss of $3.9 billion. Revenue grew 3.6% a year, compounded, over the five years to fiscal 2025. Gilead Sciences declared $3.25 a share in dividends over the last four quarters and had 1.24 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $26.2 billion of debt and $6.4 billion of cash. At the close of 6 November 2026 the market cap of Gilead Sciences was $207.1 billion.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE-29.6%
ROCE-6.0%
Operating margin-7.6%
Net margin-12.5%
FCF margin44.5%
Interest cover-2.3x
Debt to equity2.01x
Cash conversionn/a
Share count, last 12 months-0.1%
Sales CAGR, 3 years2.6%
Profit CAGR, 3 years22.8%
EPS, TTM-$3.16

At the close of 6 November 2026

Price$166.87
Market cap$207.1 billion
Stock P/En/a
Price to book15.9x
EV / EBITDAn/a
Dividend yield1.9%
Market cap / sales6.7x
52-week high$174.45
52-week low$118.15
Price, 1 year35.2%
Price CAGR, 3 years27.4%
Price CAGR, 5 years20.3%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Gilead Sciences, Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
GILDgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022 †Q2 FY2022Q3 FY2022Q4 FY2022 * †Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue7,2446,5906,2607,0427,3896,3526,5997,0517,1146,6866,9547,5457,5696,6677,0827,7697,9256,9607,8038,300
Cost of revenue2,6271,4241,4421,3951,3961,4011,4421,5652,0901,5521,5441,5741,5811,5401,5011,5691,6241,4451,5791,571
Gross profit4,6175,1664,8185,6475,9934,9515,1575,4865,0245,1345,4105,9715,9885,1275,5816,2006,3015,5156,2246,729
Gross margin64%78%77%80%81%78%78%78%71%77%78%79%79%77%79%80%80%79%80%81%
R&D2,0271,1781,1021,1491,5481,4471,4071,4571,4071,5201,3511,3951,6411,3791,4911,3461,5831,3721,7641,608
SG&A1,6501,0831,3571,2132,0201,3191,8491,3151,6071,3751,3771,4331,9061,2581,3651,3571,7941,4511,9211,641
Operating income9401972,0292,8372,2671,7051,6652,6231,612-4,3222,6448882,4522,2372,4743,3271,9842,586-10,3943,462
Operating margin13%3%32%40%31%27%25%37%23%-65%38%12%32%34%35%43%25%37%-133%42%
Interest expense238238242229226230230232252254237238248260254256254240247269
Pre-tax income759-1521,5032,4322,0311,3001,5882,3181,653-4,4862,0539562,1671,6492,4293,6412,0772,580-10,2543,063
Tax rate50%n/a24%27%20%24%35%6%14%n/a21%-31%18%20%19%16%-5%22%n/a21%
Net income38219.01,1441,7891,6401,0101,0452,1801,430-4,1701,6141,2531,7831,3151,9603,0522,1832,021-10,4962,429
Net margin5%0%18%25%22%16%16%31%20%-62%23%17%24%20%28%39%28%29%-135%29%
Diluted EPS$0.30$0.02$0.91$1.42$1.30$0.80$0.83$1.73$1.14-$3.34$1.29$1.00$1.42$1.04$1.56$2.43$1.74$1.61-$8.45$1.94
Operating cash flow3,2051,8401,8022,8632,5671,7442,3381,7552,1692,2191,3254,3092,9751,7578274,1083,3272,5443,5735,035
Capital expenditure156247143157181109139122215105130141147104107147205117140237
Free cash flow3,0491,5931,6592,7062,3861,6352,1991,6331,9542,1141,1954,1682,8281,6537203,9613,1222,4273,4334,798
Buybacks49.035272.0180792400150300150400100300350730527435230419355370
Dividends paid8949459209299159699449539439909729839731,0109941,0059941,0401,0291,039
Shares outstanding1,254m1,255m1,254m1,254m1,247m1,248m1,247m1,247m1,246m1,246m1,246m1,246m1,246m1,245m1,242m1,242m1,241m1,242m1,241m1,241m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009FY2010FY2011FY2012 †FY2013 †FY2014FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue4,2305,3367,0117,9498,3859,70311,20224,89032,63930,39026,10722,12722,44924,68927,30527,28127,11628,75429,44330,988
Cost of revenue7691,1271,5961,8702,1242,4712,8593,7884,0064,2614,3714,8534,6754,5726,6015,6576,4986,2516,2346,219
Gross profit3,4614,2095,4166,0806,2617,2318,34321,10228,63326,12921,73617,27417,77420,11720,70421,62420,61822,50323,20924,769
Gross margin81.8%78.9%77.2%76.5%74.7%74.5%74.5%84.8%87.7%86.0%83.3%78.1%79.2%81.5%75.8%79.3%76.0%78.3%78.8%79.9%
Research and development5917229401,0731,2291,7602,1202,8543,0145,0983,7345,0189,1064,9274,6014,9775,7185,9075,7996,327
Selling, general and administrative7067979471,0441,2421,4611,6992,9833,4263,3983,8784,0564,3815,1515,2465,6736,0906,0915,7746,807
Operating income2,1652,6793,5293,9623,7904,0104,52415,26522,19317,63314,1248,2004,2874,0719,9187,3307,6051,66210,022-2,362
Operating margin51.2%50.2%50.3%49.8%45.2%41.3%40.4%61.3%68.0%58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%34.0%-7.6%
Interest expense63.265.269.71092053613074126889641,1181,0779959841,0019359449771,0241,010
Pre-tax income2,2112,6733,5023,9143,6513,6124,20814,85621,65917,09713,5297,7995,1601,6698,2785,8146,8596909,796-2,534
Income tax6357028761,0248621,0381,1512,7973,5533,6098,8852,339-2041,5802,0771,2481,2472111,2861,330
Effective tax rate28.7%26.3%25.0%26.2%23.6%28.7%27.3%18.8%16.4%21.1%65.7%30.0%-4.0%94.7%25.1%21.5%18.2%30.6%13.1%n/a
Net income1,5851,9792,6362,9012,8042,5923,07512,10118,10813,5014,6285,4555,3861236,2254,5925,6654808,510-3,863
Net margin37.5%37.1%37.6%36.5%33.4%26.7%27.4%48.6%55.5%44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%-12.5%
Diluted EPS$0.82$1.03$1.41$1.66$1.77$1.64$1.81$7.35$11.91$9.94$3.51$4.17$4.22$0.10$4.93$3.64$4.50$0.38$6.78-$3.16
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by region FY2010 to FY2025

FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States4,2244,6085,5926,69518,18221,23419,35418,19416,26916,64518,21719,26718,88419,43820,59120,87670.9%
Europe3,1713,1253,3333,6145,4427,5286,3655,3114,0063,8114,1354,8744,4694,3104,6345,06417.2%
Rest of Worldn/an/an/an/an/an/an/an/an/an/an/an/a3,9283,3683,5293,50311.9%
Japann/an/an/an/a53.0n/an/an/an/an/an/an/an/an/an/an/an/a
Other Countries5556527778931,2133,877n/an/an/an/an/an/an/an/an/an/an/a
Other Internationaln/an/an/an/an/an/a4,6712,6021,8521,9932,3373,164n/an/an/an/an/a
United StatesEuropeRest of World FY2022 to FY2025Other International FY2016 to FY2021Other Countries FY2010 to FY2015Japan FY2014
8.4FY201111.2FY201332.6FY201526.1FY201722.4FY201927.3FY202127.1FY202329.4FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008FY2009FY2010FY2011FY2012 †FY2013 †FY2014FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow1,6692,1433,0802,8343,6393,1953,10512,81821,25017,04711,8988,4009,1448,16811,3849,0728,00610,82810,01914,479
Capital expenditure78.611523061.9132397134557747748590924825650579728585523563699
Free cash flow1,5902,0282,8502,7723,5072,7982,97112,26120,50316,29911,3087,4768,3197,51810,8058,3447,42110,3059,45613,780
Free cash flow margin37.6%38.0%40.6%34.9%41.8%28.8%26.5%49.3%62.8%53.6%43.3%33.8%37.1%30.5%39.6%30.6%27.4%35.8%32.1%44.5%
Cash from investing-1,302-179-2,216-1,9383,590-11,846-254-1,823-12,475-11,985-16,06914,355-7,817-14,615-3,131-2,466-2,265-3,449-4,793-10,656
Cash from financing-171-1,475-1,051-1,3391,764563-2,544-3,025-5,884-9,7253,393-12,318-7,634770-8,877-6,469-5,125-3,433-7,745-4,686
Depreciation and amortisationn/an/an/a127142146n/an/an/an/an/an/an/a1,4882,0292,1232,6542,7812,770n/a
Share-based compensation185153181200192209252360382380638845636643635637766835894913
Buybacks4881,9709984,0232,3836675825,34910,00211,0019542,9001,7491,5835461,3961,0001,1501,9221,374
Dividends paidn/an/an/an/an/an/a0.00.01,8742,4552,7312,9713,2223,4493,6053,7093,8093,9184,0034,102
Dividend per sharen/an/an/an/an/an/a$0.00$0.00$1.29$1.84$2.08$2.28$2.52$2.72$2.84$2.92$3.00$3.08$3.16n/a
Diluted shares, weighted1,929m1,918m1,868m1,747m1,580m1,583m1,695m1,647m1,521m1,358m1,319m1,308m1,277m1,263m1,262m1,262m1,258m1,255m1,255m1,251m
Shares outstanding at period endn/a1,820m1,800m1,604m1,506m1,519m1,534m1,499m1,422m1,310m1,308m1,282m1,266m1,254m1,254m1,247m1,246m1,246m1,241m1,241m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009FY2010FY2011FY2012 †FY2013 †FY2014FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity3,7534,2736,3675,8646,7399,31011,36915,42618,53418,88720,44221,38722,52518,20221,06921,24022,83319,33022,70313,040
Non-controlling interestn/a19313825812824137539357947659.014712519.0-5.0-31.0-84.0-84.0-84.0-84.0
Redeemable equityn/an/an/an/an/a7.164.015.02.00.0n/an/an/an/an/an/an/an/an/an/a
Debtn/a1,0981,1552,8397,6068,2246,63612,40422,05526,34633,54227,32224,59331,40226,69525,22924,98726,71024,93726,231
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a626608489467546498503n/a
Other liabilitiesn/a1,3732,0382,6322,8303,4584,1356,42610,54611,26816,24014,81913,75818,17619,70416,26613,84312,54110,96412,221
Total liabilities and equityn/a6,9379,69911,59317,30321,24022,57934,66451,71656,97770,28363,67561,62768,40767,95263,17162,12558,99559,02351,408
Owned
Fixed assetsn/a5297007017741,1001,1661,6742,2762,8653,2954,0064,5024,9675,1215,4755,3175,4145,6065,945
Goodwilln/an/a4635331,0041,0611,1691,1721,1721,1724,1594,1174,1178,1088,3328,3148,3148,3148,3148,314
Intangible assetsn/an/a9238631,06311,73611,90011,07310,2478,97117,10015,73813,78633,12633,45528,89426,45419,94816,97813,424
Investmentsn/a1,7802,6324,41080.27784581,69913,35724,15129,10613,57214,2091,9132,4912,2182,3420.03,0420.0
Cash and equivalents9681,4591,2739089,8841,8042,11310,02712,8518,2297,58817,94011,6315,9975,3385,4126,0859,9917,5646,437
Receivablesn/a1,0231,3901,6221,9511,7512,1824,6355,8544,5143,8513,3273,5824,8924,4934,7774,6604,4204,9135,007
Inventoryn/a9281,0521,2041,3901,7451,6971,3861,9551,5878018149221,6831,6181,5071,7871,7101,7741,896
Other assetsn/a1,2171,2671,3511,1571,2641,8942,9984,0045,4884,3834,1618,8787,7217,1046,5747,1669,19810,83210,385
Total assetsn/a6,9379,69911,59317,30321,24022,57934,66451,71656,97770,28363,67561,62768,40767,95263,17162,12558,99559,02351,408
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded-1.0%3.6%2.6%6.5%
Profit growth, compounded-7.3%133.3%22.8%n/a
Return on equity, average26.0%23.2%21.6%37.5%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Gilead Sciences' revenue in fiscal 2025?

Gilead Sciences (GILD) reported revenue of $29.4 billion for fiscal 2025, the year ended 31 December 2025, up 2.4% on the year before.

How much did Gilead Sciences earn in fiscal 2025?

Net income was $8.5 billion for fiscal 2025, and diluted earnings per share $6.78.

What is Gilead Sciences' market cap?

The market cap of Gilead Sciences was $207.1 billion at the close of 6 November 2026.

Does Gilead Sciences pay a dividend?

Yes. Gilead Sciences declared $3.25 a share in dividends over the four quarters to 30 September 2026.

How much debt does Gilead Sciences have?

At 30 September 2026 Gilead Sciences carried $26.2 billion of debt and $6.4 billion of cash.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
38 companies share its SEC industry code (Biological Products, (No Diagnostic Substances)); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on GILD

Dividends$3.25 a share over the four quarters to 30 September 2026, a 1.95% yield
Filings18 in twelve months: 9 current reports (8-K), about 4 results of operations; 2 material agreement; 2 other events; 2 regulation FD disclosure; 1 new financial obligation
Planned insider sales45 Form 144 notices in twelve months, $119.7 million; latest 6 November 2026
Options tapeput/call 0.9 by open interest at the 6 November 2026 close; the straddle prices a 4.2% move to 13 November 2026
13F holders2,299 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading85 sales and 0 purchases on Form 4 in twelve months
Congress1 House trade disclosed in six months
Short interest20.3 million shares short, 3.72 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202630 October 2026EDGAR
10-Q30 June 20266 August 2026EDGAR
10-Q31 March 20267 May 2026EDGAR
10-K31 December 202524 February 2026EDGAR
10-Q30 September 20257 November 2025EDGAR
10-Q30 June 20257 August 2025EDGAR
10-Q31 March 20257 May 2025EDGAR
10-K31 December 202428 February 2025EDGAR
10-Q30 September 202412 November 2024EDGAR
10-Q30 June 20248 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.